ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2328

Increased Risk of Stroke In Patients With Psoriasis: A Systematic Review And Meta-Analysis

Rubab Rizwan, Sehneet Grewal, Sri Varsha Banda and Mohammad Hazique, Nuvance Health, poughkeepsie, NY

Meeting: ACR Convergence 2025

Keywords: Stroke

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Psoriasis, affecting 2–3% of the global population, is a chronic inflammatory disease with systemic effects beyond the skin. Its immune-mediated inflammation contributes to cardiovascular comorbidities including hypertension, diabetes, and atherosclerosis. Th1/Th17-driven pathways accelerate vascular risk, linking psoriasis to stroke. However, data on stroke risk remain limited due to small cohorts and insufficient confounder adjustment.

Methods: This meta-analysis evaluated the association between psoriasis and stroke by systematically reviewing observational studies published through December 2024. Study selection followed PRISMA guidelines, extracting data on patient characteristics and adjusted risk estimates.

Results: This meta-analysis of 18 studies encompassing 705,602 psoriasis patients and over 17.9 million controls demonstrated a significant association between psoriasis and stroke, with a pooled hazard ratio (HR) of 1.24 (95% CI: 1.15–1.35). Stratified analyses showed elevated stroke risk across all severities: mild (HR: 1.09; 95% CI: 1.02–1.16), overall (HR: 1.34; 95% CI: 1.05–1.73), and severe psoriasis (HR: 1.36; 95% CI: 1.21–1.53). Region-specific estimates indicated consistent associations in Asia (HR: 1.08), Europe (HR: 1.26), and North America (HR: 1.49), though with some heterogeneity. Age subgroup analysis also confirmed increased stroke risk in both older (≥45 years, HR: 1.27) and younger ( < 45 years, HR: 1.18) patients. No significant publication bias or small-study effects were detected by funnel plot analysis and statistical testing.

Conclusion: This analysis confirms that psoriasis is associated with an increased risk of stroke, particularly in patients with severe disease. The association remains consistent across age groups and geographic regions. These findings highglight the need for routine cardiovascular risk assessment in psoriasis care. Future research should explore targeted anti-inflammatory therapies and lifestyle interventions to mitigate stroke risk in this population.

Supporting image 1


Disclosures: R. Rizwan: None; S. Grewal: None; S. Banda: None; M. Hazique: None.

To cite this abstract in AMA style:

Rizwan R, Grewal S, Banda S, Hazique M. Increased Risk of Stroke In Patients With Psoriasis: A Systematic Review And Meta-Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/increased-risk-of-stroke-in-patients-with-psoriasis-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-risk-of-stroke-in-patients-with-psoriasis-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology